Glen Eagle Advisors’s Voyager Therapeutics VYGR Stock Holding History

Glen Eagle Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100	Closed	-$715	–	1029
2020 Q4	$715	Hold	100	–	–	﹤0.01%	926
2020 Q3	$1.07K	Hold	100	–	–	﹤0.01%	842
2020 Q2	$1.26K	Hold	100	–	–	﹤0.01%	796
2020 Q1	$915	Hold	100	–	–	﹤0.01%	761
2019 Q4	$1.4K	Hold	100	–	–	﹤0.01%	813
2019 Q3	$1.72K	Hold	100	–	–	﹤0.01%	719
2019 Q2	$2.72K	Hold	100	–	–	﹤0.01%	674
2019 Q1	$1.91K	Sell	100 -125	-56%	-$1.63K	﹤0.01%	657
2018 Q4	$2.12K	Hold	225	–	–	﹤0.01%	622
2018 Q3	$4.26K	Buy	+225	New	+$4.32K	﹤0.01%	581
2017 Q3	–	Sell	-500	Closed	-$4.48K	–	655
2017 Q2	$4.48K	Hold	500	–	–	﹤0.01%	486
2017 Q1	$6.62K	Hold	500	–	–	0.01%	428
2016 Q4	$6.37K	Buy	+500	New	+$6.42K	0.01%	414

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WHCM

Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Glen Eagle Advisors's VYGR Position: Q1 2021 in Review

Glen Eagle Advisors sold out of Voyager Therapeutics (VYGR) in Q1 2021, closing a stake of 100 shares — an estimated $715 sold.

Glen Eagle Advisors first reported a position in VYGR in Q4 2016 and held it in 13 quarters. The position peaked at $6.62K in Q1 2017. 101 funds tracked by Wall St. Rank hold VYGR as of Q1 2021.

Glen Eagle Advisors reported no remaining Voyager Therapeutics position as of Q1 2021 after selling out during the quarter.
Glen Eagle Advisors sold 100 Voyager Therapeutics shares in Q1 2021, an estimated $715.
Glen Eagle Advisors first reported a position in Voyager Therapeutics in Q4 2016 and held it in 13 quarters.
Glen Eagle Advisors's Voyager Therapeutics position peaked at $6.62K in Q1 2017.
101 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2021.

Based on Glen Eagle Advisors's 13F filing for Q1 2021, filed 13 Aug 2024.